[PP.01.27] DYSLIPIDEMIA IN HYPERTENSIVE PATIENTS UNDERGOING 24-HOURS AMBULATORY BLOOD PRESSURE MONITORING

Le résumé fourni par la source

Objective: Hypertension and dyslipidemia represent two of the most relevant modifiable cardiovascular risk (CVR) factors and they often coexist. The aim of our study was to evaluate the characteristics of the lipid profile of a large unselected hypertensive population referred to our Centre, to underline the magnitude of this association and possible lacks in the management of dyslipidemia. Design and method: Retrospective study on 1440 hypertensives referred to our Hypertension Centre between 2010 and 2015. Inclusion criteria were age >=18 years, a 24-hour ambulatory blood pressure monitoring (ABPM) and a complete lipid profile: total cholesterol (TC), HDL cholesterol (HDL-c) and triglycerides (TG). Dyslipidemia was defined by the presence of at least one of these characteristics: TC >=200 mg/dl, calculated LDL cholesterol (cLDL) values higher than those recommended based on individual CVR, HDL-c<40 mg/dl in men and <50 mg/dl in women, TG >=150 mg/dl. Results: Mean age: 55.9 ± 13.4 years. Male sex: 823 (57.2%). Overweight/obese: 68%. Smokers: 18.1%. Diabetics: 10.7%. Dyslipidemia: 82.6%. Patients with peripheral arterial disease (PAD): 23,7%. Mean eGFR: 75.0 ± 15.6 ml/min/1.73m2. Mean TC: 205.9 ± 39.7 mg/dl. Mean HDL-c: 51.8 ± 13.7 mg/dl. Median TG: 111 mg/dl (82–157). Mean cLDL: 129.2 ± 34.5 mg/dl. Drug therapy: 19% (statins 87.6%, ezetimibe 6.2%, others 2.2%). At target cLDL: 39% (all patients), 42.9% (treated patients). Females were less controlled, despite the same treatment rate with lipid-lowering drugs. Diabetics were also less controlled, despite a higher rate of treatment with lipid-lowering drugs. Patients with PAD not treated with lipid-lowering drugs were 78.3%. TG>=150 mg/dl: 28% (all patients), 33% (treated patients). Low HDL-c (according to sex): 28.3%. Statins frequencies: simvastatin (34.1%), atorvastatin (27.8%), rosuvastatin (13.2%), pravastatin (10.3%), others (2.2%). High intensity statins were taken only by 2% of treated patients. The hypertensives controlled by therapy were 29.9% and patients with both controlled hypertension and cLDL were only 12%. Conclusions: Our data show the frequent association between hypertension and dyslipidemia. Patients with at least one alteration of the lipid profile were often untreated with lipid-lowering drugs, even in the presence of increased CVR. Whenever treated, they received low-medium intensity statins and they often did not reach their therapeutic goals.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.